Denali Therapeutics Inc. is a clinical-stage biotechnology company dedicated to discovering and developing therapies for neurodegenerative and lysosomal storage diseases. The company's core innovation is its proprietary Transport Vehicle (TV) platform, which includes Enzyme Transport Vehicles and Antibody Transport Vehicles designed to deliver large-molecule drugs across the blood-brain barrier via receptor-mediated transcytosis. Denali's research and development pipeline includes candidates targeting Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Hunter syndrome. Operating primarily as an R&D-driven organization, Denali advances its programs through a combination of internal development and strategic collaborations with major pharmaceutical companies. The company generates revenue primarily through upfront payments, research funding, and milestone payments from these partnerships rather than commercial product sales.
